Table 1.
Participant demographics, stratified by race
| African American | White | p | |
|---|---|---|---|
| n | 131 | 685 | |
| Age (years old) (mean (SD)) | 70.64 (8.3) | 71.64 (9.0) | 0.247 |
| Sex = Male (%) | 45 (34.4) | 282 (41.2) | 0.164 |
| Education (years) (mean (SD)) | 15.36 (2.8) | 16.12 (2.5) | 0.002 |
| APOE ε4+ (%) | 54 (42.2) | 228 (33.6) | 0.082 |
| PRS (mean (SD)) | 32.23 (12.2) | 26.62 (22.7) | <0.001 |
| AD Signature Z (mean (SD)) | −0.26 (0.6) | 0.10 (0.6) | <0.001 |
| Subset of participants who had completed PET amyloid | |||
| n | 70 | 434 | |
| Age (years old) (mean (SD)) | 67.56 (38.6) | 69.62 (9.1) | 0.076 |
| Sex = Male (%) | 27 (38.6) | 166 (38.2) | 1.000 |
| Education (years) (mean (SD)) | 15.19 (2.8) | 16.06 (2.6) | 0.010 |
| APOE ε4+ (%) | 27 (39.7) | 143 (33.2) | 0.359 |
| PRS (mean (SD)) | 31.56 (11.9) | 26.72 (10.5) | <0.001 |
| Centiloid (mean (SD)) | 5.8 (14.9) | 15.8 (30.7) | 0.051 |
| Subset of participants who had completed PET tau | |||
| n | 34 | 262 | |
| Age (years old) (mean (SD)) | 68.82 (5.7) | 69.70 (8.3) | 0.552 |
| Sex = Male (%) | 15 (44.1) | 111 (42.4) | 0.992 |
| Education (years) (mean (SD)) | 15.15 (2.5) | 16.52 (2.2) | 0.001 |
| APOE ε4+ (%) | 13 (38.2) | 91 (34.7) | 0.832 |
| PRS (mean SD)) | 28.79 (11.7) | 26.73 (11.8) | 0.335 |
| Tauopathy (mean (SD)) | 1.2 (0.2) | 1.2 (0.2) | 0.761 |
| Subset of participants who had completed resting state functional MRI | |||
| n | 55 | 317 | |
| Age (years old) (mean (SD)) | 69.03 (9.03) | 71.24 (9.40) | 0.107 |
| Sex = Male (%) | 19 (34.5) | 133 (42.0) | 0.377 |
| Education (years) (mean (SD)) | 16.09 (2.61) | 15.83 (2.50) | 0.478 |
| APOE ε4+ (%) | 24 (46.3) | 97 (30.9) | 0.039 |
| PRS (mean (SD)) | 33.80 (10.9) | 26.55 (10.8) | <0.001 |
| Global rs-fc Signature | 0.91 (0.14) | 0.94 (0.15) | 0.313 |
Note. SD = standard deviation; APOE ε4+ = APOE ε44 positive; AD = Alzheimer’s disease; rs-fc = resting-state functional connectivity; PRS = polygenic risk score